Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 23, 2026Journal of Crohn s and Colitis

P0785One-Year Efficacy of Upadacitinib in Perianal Crohn’s Disease: A Multicenter Cohort Study.

View Full Paper
Ask AI
Bookmark
Share

Authors

NRN RichardInsermPSP SeksikInsermRAR. AltweggCentre Hospitalier Universitaire de Montpellier

Discussion

Loading...

Member takes

Overview

Multicenter cohort study reveals upadacitinib achieves clinical remission in perianal Crohn’s disease, suggesting potential for treatment effectiveness.

Key Points

  • Evaluate the real-world efficacy of upadacitinib in patients with perianal Crohn’s disease.
  • Retrospective cohort study across 13 French centers
  • Included patients with active perianal Crohn's disease treated with upadacitinib
  • Assessed clinical remission, clinical response, MRI response, and treatment failure
  • Achieved clinical remission in approximately 26% of patients with fistulizing perianal CD at 12 months
  • 63% showed clinical response at 3 months, decreasing to 30% at 12 months
  • MRI response was observed in 64% and MRI remission in 7% after 12 months
  • 16% of patients underwent perianal drainage surgery
  • 27% discontinued upadacitinib due to lack of efficacy

Cite This Study

Richard et al. (2026) studied this question.

synapsesocial.com/papers/69730ed4c8125b09b0d1ea2ahttps://doi.org/10.1093/ecco-jcc/jjaf231.966
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1P0955Efficacy of Anti-TNF Agents for the Treatment of Anoperineal Fistulas Without Luminal Crohn’s Disease: A Multicenter Cohort Study.2026
  2. 2OP27Integrative single-cell, spatial, and clinical analysis supports JAK1 inhibition as a compelling therapeutic strategy in perianal Crohn’s disease2026
  3. 3P1101Upadacitinib for the treatment of perianal Crohn’s disease: effectiveness and safety. A single centre real-world experience2026
  4. 4DOP007Ustekinumab for Fistulizing Perianal Crohn’s Disease: week-48 results from the USTAP Randomized Placebo-ControlledTrial2026 · 2 citations
  5. 5P0493Real-World Effectiveness of Upadacitinib in Treatment-Experienced Crohn’s Disease Patients: The UPITA-Crohn Study2026